The association was much stronger for those with triple-negative cancer (OR = 6.70) (95% OR 2.18–20.56, p = 0.001) than for those with HER2-positive cancer (OR = 1.65) (95% OR 0.70–3.88, p = 0.25). This evidence concerns the gene ERBB2 and cancer.